Novartis | NVS - Gross Profit On Sales


Novartis reported $10.07B in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Amgen USD 6.89B 415M Dec/2025
AstraZeneca USD 12.61B 225M Mar/2026
Bausch Health Companies USD 2B 67M Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Canopy Growth CAD 8.26M 13.2M Mar/2026
Corcept Therapeutics USD 162.02M 37.56M Mar/2026
Drreddys Laboratories INR 43.04B 3.77B Mar/2026
Eli Lilly USD 15.92B 1.33B Dec/2025
Gilead Sciences USD 5.52B 791M Mar/2026
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Glaxosmithkline GBP 5.75B 2.99B Mar/2026
J&J USD 18.55B 1.31B Jun/2026
Merck USD 10.85B 2.57B Dec/2025
Novartis USD 10.07B 184M Mar/2026
Novartis USD 10.07B 758M Mar/2026
Pacira USD 126.64M 15.61M Mar/2026
Perrigo USD 325.5M 36.7M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Phibro Animal Health USD 133.5M 12.6M Dec/2025
Prestige Brands USD 157.37M 5.79M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Sanofi EUR 8.11B 343M Mar/2026
Supernus Pharmaceuticals USD 129.36M 34.68M Mar/2026
Zoetis USD 1.62B 20M Mar/2026